

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/029990 A1

(51) International Patent Classification:

A61K 31/4468 (2006.01) A61P 25/28 (2006.01)
A61P 25/16 (2006.01) A61P 43/00 (2006.01)
A61P 25/24 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2024/040491

(22) International Filing Date:

01 August 2024 (01.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/530,291 02 August 2023 (02.08.2023) US
63/554,437 16 February 2024 (16.02.2024) US

(71) Applicant: ACADIA PHARMACEUTICALS INC.

[US/US]; 12830 El Camino Real, Suite 400, San Diego, Cal-
ifornia 92130 (US).

(72) Inventor: BURSTEIN, Ethan S.; c/o ACADIA Pharma-

ceuticals Inc., 12830 El Camino Real, Suite 400, San Diego,
California 92130 (US).

(74) Agent: CARROLL, William A. et al.; Michael Best &

Friedrich LLP, N19 W24133 Riverwood Drive, Ste. 200,
Waukesha, Wisconsin 53188 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: 3-(4-CYCLO-PROPOXYBENZYL)-1-(2,4-DIFLUOROBENZYL)-1-(1-METHYLPYPERIDIN-4-YL)UREA FOR USE
IN THE TREATMENT OF DISEASES ASSOCIATED WITH THE SEROTONIN-RECEPTOR 5-HT

(57) Abstract: The present disclosure relates to pharmaceutical compositions containing 3-[(1-cyclopropoxyphenyl)-methyl]-1-[(2,4-
difluorophenyl)-methyl]-1-(1-methylpiperidin-4-yl)urea, or a pharmaceutically acceptable salt and/or pharmaceutically acceptable salt
hydrate thereof, and the use thereof for treating diseases and conditions, including those associated with the serotonin receptor, and for
modulating the activity serotonin receptor 5-HT_{2A}.

WO 2025/029990 A1